The legal, regulatory and marketing hurdles faced by companies with commercial cannabinoids have not deterred new entrants seeking to build better mousetraps. Although many companies in the field continue to rely on the cannabis plant as the starting point for their R&D efforts, some have turned to what they consider next-generation drug development to overcome concerns about pharmacokinetic consistency.